Description:

miRNAshavebeenimplicatedintheregulationofvariousBIOLOGicalprocessessuchascelldeathandcellproliferation.Theycanactasoncogenesandtumorsuppressorgenes,playingacrucialroleintumorogenesis.ThechangeintheexpressionlevelofmiRNAsisassociatedwithdysfunctionoftheircorrespondingprotein-codinggenetargets,manyofwhichareinvolvedintheinitiationandprogressionofcancer.Forexample,BCL2oncogeneistargetedbymiR-15aandmiR-16,whilePTENtumorsuppressoristargetedbymiR-21,andHOXD10,Pak,MYOD1andER,andHer2 aretargeted bymiR-10b, miR-7,miR-206,and miR-125a,respectively.
SignosisdevelopedcancermiRNAplateassaykitIforquantitativelyprofilingtheexpressionofsevenwell-knowncancerrelatedmiRNAs,whicharemiRNA-15a,miR-16,miR-21,miR10b,miR-7,miR-125aandmiR206.RNU48isincludedfornormalization.

Principle:

IntheproprietarymiRNAplateassay,onemiRNAmoleculeisflankedbyacaptureoligoandabiotinateddetectionoligothroughtwobridgesoligos.OneofthebridgeoligosispartiallyhybridizedwiththemiRNAmoleculeandthecaptureoligoandanotherwiththemiRNAandthedetectionoligo.Thehybridisimmobilizedontoplatethroughhybridizationwithanimmobilizedoligoanddetectedbyastreptavidin-HRPconjugateandchemiluminecscentsubstrate.ThishybridstructureissensitivetothesequenceofthemiRNAmolecule.OnenucleotidedifferencewillpreventtheformationofthehybridandthereforemiRNAisoformcanbedifferentiated,whichnormallyishardtotacklewithNorthernblot.Inaddition,thesensitivityoftheassayishigherthanmiRNANorthernblotassay.

Data:

ExpressionofmiRNAswasanalyzedwith0.5ugtotalRNAfromnormalliverandT47Dcellsrespectively.Theassaywassubjectedtochemiluminescentplatereader.

Signosis 是一家专业的生物分析供应商，致力于基于微孔板分析技术的生命科学研究产品的开发、生产和销售。Signosis 成立于2007年，坐落于世界研发中心--美国硅谷的中心地带。公司专注于细胞因子、转录因子、miRNA及疾病标志物等重要调控因子和标志物的研究，基于自有专利技术，开发完成400多种先进而独特的用于发现、筛选和分析的生命科学研究产品。Signosis 产品销售遍布北美、欧洲、亚洲及中东等主要国家和地区，客户涵盖美国国立卫生研究院、哈佛大学、耶鲁大学等著名研究机构以及众多制药公司